title: Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension.
abstract: OBJECTIVE
  To assess whether long term treatment with epoprostenol might restore primary non-responsiveness to nitric oxide (NO) in patients with primary pulmonary hypertension.
  
  
  METHODS
  Seven patients with primary pulmonary hypertension receiving intravenous epoprostenol continuously because of failure of NO to influence pulmonary haemodynamics during initial testing were followed over a period of 13-29 months. Afterwards, acute vascular reactivity towards NO was tested again during right heart catheterisation.
  
  
  RESULTS
  Administration of NO after continuous epoprostenol treatment for a mean period of 18 months improved arterial oxygen saturation (p < 0.01) and cardiac index (p < 0.05), and decreased mean pulmonary artery pressure (p < 0.01) and total pulmonary vascular resistance (p < 0.01) in patients previously unresponsive to NO.
  
  
  CONCLUSIONS
  Long term treatment with epoprostenol reverts initial refractoriness to NO in patients with primary pulmonary hypertension. Thus the addition of NO to epoprostenol treatment might cause further improvement in the course of the disease.
authors.affiliation: Department of Internal Medicine IV, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria. rolf.ziesche@akh-wien.ac
authors.forename: R
authors.initials: R
authors.lastname: Ziesche
authors.forename: V
authors.initials: V
authors.lastname: Petkov
authors.forename: K
authors.initials: K
authors.lastname: Wittmann
authors.forename: J
authors.initials: J
authors.lastname: Kopatschka
authors.forename: L
authors.initials: L
authors.lastname: Stiebellehner
authors.forename: P
authors.initials: P
authors.lastname: Schenk
authors.forename: P
authors.initials: P
authors.lastname: Germann
authors.forename: G
authors.initials: G
authors.lastname: Röder
authors.forename: R
authors.initials: R
authors.lastname: Ullrich
authors.forename: L H
authors.initials: LH
authors.lastname: Block
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol